MJN-neuro has opened crowdequity round of one million euros on the Capital Cell platform to fund the business plan of the new device MJN-Seras, the first portable device that is able to predict the likelihood of suffering an epileptic seizure. The company, a CataloniaBio & HealthTech member, has already exceeded one million euros in less than 5 months and expects to reach 120%. In addition, the round has been extended to allow the entry of a major Danish Family Office.
During this period, the value of the company has tripled, and, after the participation of American and Spanish investors, it now reaches 12 million euros. This economic boost is accompanied by the agreements that mjn-neuro has established with international markets.
The funding will allow the company to market its device, mjn-SERAS, in Europe taking advantage of market traction and start a new round next year. So far, they have reached an agreement with the United Kingdom to distribute the device in that country, with the help of expert distributor Epilepsy Alarms, and a pre-agreement has been reached with another distributor in the Netherlands. Thanks to EIT Health’s Bridgehead 2020 program, they have also embarked on an approach to the German market through Medical Valley, a key move for the mjn-neuro expansion strategy.
You may also be interested in:
Comments